OptiNose, Inc. (NASDAQ:OPTN) Q3 2023 Earnings Call Transcript

Unidentified Analyst: Got it. That makes sense. And then next on the payer landscape, with the expanded label, what would you think would be the net pricing per prescription would look like? Any additional details you could give there, would be helpful? Thank you.

Dr. Ramy Mahmoud: So, it’s hard to speak with confidence about the future when a variety of actors are involved. So I can’t be certain. But our belief, as I think we’ve said before is that, we don’t think there will be any material change to the pricing of the product based purely on the approval. In other words, the price of the product and the net price of the product the day after approval will be the same as it was the day before approval.

Unidentified Analyst: Got it. Thank you.

Operator: Thank you. I’m showing no more questions at this time. I’d like to hand the conference back over to Dr. Mahmoud for closing remarks.

Dr. Ramy Mahmoud: So in conclusion, I think, we’re all very happy with how this year has gone so far. As you’ve seen illustrated through third quarter, the company has really delivered on stabilizing revenue at dramatically lower cost. We think the company is now very well positioned to be a stable foundation to efficiently launch into a new indication in next year. And in the next month or two here, we’re really looking forward to that opportunity. Thank you all again for joining this morning and we look forward to talking to you again soon.

Operator: This concludes today’s conference call. Thank you for your participation. You may now disconnect. Everyone have a wonderful day.